Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 9OTHER 7NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 41Cisplatin 40Paclitaxel 35Radiotherapy 32Docetaxel 19Pemetrexed 18Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 10Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Folic Acid × Thoracic × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡